Skip to content

Cancer Health Center

Font Size

Adult Acute Myeloid Leukemia Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (06 / 24 / 2013)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Untreated Adult Acute Myeloid Leukemia

Recommended Related to Cancer

Overview

Cannabis, also known as marijuana, is a plant grown in many parts of the world (see Question 1). The use of Cannabis for medicinal purposes dates back to ancient times (see Question 3). By federal law, possessing Cannabis is illegal in the United States (see Question 1). In the United States, Cannabis is a controlled substance that requires special licensing for its use (see Question 1 and Question 3). Cannabinoids are active chemicals in Cannabis that cause drug -like effects...

Read the Overview article > >

Added text to state that the choice of anthracycline and the anthracycline dose-intensity may influence the survival of patients with acute myeloid leukemia (AML).

Added text to state that in patients aged 60 years and younger, outcomes for those receiving daunorubicin were superior to those receiving more traditional dosing; complete remission rate was 71% versus 57%, and median survival was 24 months versus 16 months (cited Fernandez et al. as reference 7); however, no comparison data for daunorubicin administered at different dosing rates are available.Two studies examined when idarubicin versus daunorubicin were administered to elderly patients and found that overall survival was not impacted by the choice of anthracycline, but the percentage of long-term disease-free survivors in a mixed-cure model did appear to be impacted (cited Gardin et al. as reference 8). The addition of the CD33-directed immunotoxin gemtuzumab ozogamicin to cytarabine plus anthracycline or clofarabine plus anthracycline in patients aged 51 to 79 years led to a small increase in median survival (cited 2012 Burnett et al. as reference 9). In contrast, gemtuzumab did not improve the 1-year survival rate of elderly patients receiving low-dose cytarabine, although the CR rate increased from 17% to 30% (cited 2013 Burnett et al. as reference 10).

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

    This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http:// cancer .gov or call 1-800-4-CANCER.

    WebMD Public Information from the National Cancer Institute

    Last Updated: September 04, 2014
    This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
    1
    Next Article:

    Today on WebMD

    Colorectal cancer cells
    New! I AM Not Cancer Facebook Group
    Lung cancer xray
    See it in pictures, plus read the facts.
     
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Ovarian cancer illustration
    Real Cancer Perspectives
     
    Jennifer Goodman Linn self-portrait
    Blog
    what is your cancer risk
    HEALTH CHECK
     
    colorectal cancer treatment advances
    Video
    breast cancer overview slideshow
    SLIDESHOW
     
    prostate cancer overview
    SLIDESHOW
    lung cancer overview slideshow
    SLIDESHOW
     
    ovarian cancer overview slideshow
    SLIDESHOW
    Actor Michael Douglas
    Article